Literature DB >> 25627085

Interaction of tetraspan(in) TM4SF5 with CD44 promotes self-renewal and circulating capacities of hepatocarcinoma cells.

Doohyung Lee1, Juri Na2, Jihye Ryu1, Hye-Jin Kim1, Seo Hee Nam3, Minkyung Kang1,4, Jae Woo Jung3, Mi-Sook Lee1, Haeng Eun Song1, Jungeun Choi3, Gyu-Ho Lee1, Tai Young Kim1, June-Key Chung2,5, Ki Hun Park6, Sung-Hak Kim7, Hyunggee Kim7, Howon Seo8, Pilhan Kim8, Hyewon Youn2,5, Jung Weon Lee1,3.   

Abstract

UNLABELLED: Tumor metastasis involves circulating and tumor-initiating capacities of metastatic cancer cells. Epithelial-mesenchymal transition (EMT) is related to self-renewal capacity and circulating tumor cell (CTC) characteristics for tumor metastasis. Although tumor metastasis is a life-threatening, complicated process that occurs through circulation of tumor cells, mechanistic aspects of self-renewal and circulating capacities have been largely unknown. Hepatic transmembrane 4 L six family member 5 (TM4SF5) promotes EMT for malignant growth and migration, so it was rationalized that TM4SF5, as a hepatocellular carcinoma (HCC) biomarker, might be important for metastatic potential. Here, self-renewal capacity by TM4SF5 was mechanistically explored using hepatocarcinoma cells with or without TM4SF5 expression, and we explored whether they became CTCs using mouse liver-orthotopic model systems. We found that TM4SF5-dependent sphere growth correlated with CD24(-) , aldehyde dehydrogenase (ALDH) activity, as well as a physical association between CD44 and TM4SF5. Interaction between TM4SF5 and CD44 was through their extracellular domains with N-glycosylation modifications. TM4SF5/CD44 interaction activated proto-oncogene tyrosine-protein kinase Src (c-Src)/signal transducer and activator of transcription 3 (STAT3)/Twist-related protein 1 (Twist1)/B-cell-specific Moloney murine leukemia virus integration site 1 (Bmi1) signaling for spheroid formation, whereas disturbing the interaction, expression, or activity of any component in this signaling pathway inhibited spheroid formation. In serial xenografts using 200∼5,000 cells per injection, TM4SF5-positive tumors exhibited subpopulations with locally increased CD44 expressions, supporting for tumor cell differentiation. TM4SF5-positive, but not TM4SF5- or CD44-knocked-down, cells were identified circulating in blood 4-6 weeks after orthotopic liver injection using in vivo laser scanning endomicroscopy. Anti-TM4SF5 reagent blocked their metastasis to distal intestinal organs.
CONCLUSION: TM4SF5 promotes self-renewal and CTC properties supported by TM4SF5(+) /CD44(+(TM4SF5-bound)) /ALDH(+) /CD24(-) markers during HCC metastasis.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25627085     DOI: 10.1002/hep.27721

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  28 in total

1.  Clinicopathological significance of TM4SF5 expression in human hepatocellular carcinoma tissues.

Authors:  Baojin Xu; Wu Lv; Xiaoyan Li; Lina Zhang; Jie Lin
Journal:  Oncol Lett       Date:  2019-04-03       Impact factor: 2.967

2.  miR-151a-3p-rich small extracellular vesicles derived from gastric cancer accelerate liver metastasis via initiating a hepatic stemness-enhancing niche.

Authors:  Bowen Li; Yiwen Xia; Jialun Lv; Weizhi Wang; Zhe Xuan; Cen Chen; Tianlu Jiang; Lang Fang; Linjun Wang; Zheng Li; Zhongyuan He; Qingya Li; Li Xie; Shengkui Qiu; Lu Zhang; Diancai Zhang; Hao Xu; Zekuan Xu
Journal:  Oncogene       Date:  2021-09-17       Impact factor: 9.867

3.  Machine learning-assisted elucidation of CD81-CD44 interactions in promoting cancer stemness and extracellular vesicle integrity.

Authors:  Tujin Shi; Yang Shen; Nurmaa K Dashzeveg; Huiping Liu; Erika K Ramos; Chia-Feng Tsai; Yuzhi Jia; Yue Cao; Megan Manu; Rokana Taftaf; Andrew D Hoffmann; Lamiaa El-Shennawy; Marina A Gritsenko; Valery Adorno-Cruz; Emma J Schuster; David Scholten; Dhwani Patel; Xia Liu; Priyam Patel; Brian Wray; Youbin Zhang; Shanshan Zhang; Ronald J Moore; Jeremy V Mathews; Matthew J Schipma; Tao Liu; Valerie L Tokars; Massimo Cristofanilli
Journal:  Elife       Date:  2022-10-04       Impact factor: 8.713

Review 4.  Pancreatic cancer stem cell markers and exosomes - the incentive push.

Authors:  Sarah Heiler; Zhe Wang; Margot Zöller
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

5.  Lysyl-tRNA synthetase-expressing colon spheroids induce M2 macrophage polarization to promote metastasis.

Authors:  Seo Hee Nam; Doyeun Kim; Doohyung Lee; Hye-Mi Lee; Dae-Geun Song; Jae Woo Jung; Ji Eon Kim; Hye-Jin Kim; Nam Hoon Kwon; Eun-Kyeong Jo; Sunghoon Kim; Jung Weon Lee
Journal:  J Clin Invest       Date:  2018-10-08       Impact factor: 14.808

Review 6.  Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications.

Authors:  Terence Kin-Wah Lee; Xin-Yuan Guan; Stephanie Ma
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-09-09       Impact factor: 46.802

7.  A rapid and quantitative method to detect human circulating tumor cells in a preclinical animal model.

Authors:  Shih-Hsin Tu; Yi-Chen Hsieh; Li-Chi Huang; Chun-Yu Lin; Kai-Wen Hsu; Wen-Shyang Hsieh; Wei-Ming Chi; Chia-Hwa Lee
Journal:  BMC Cancer       Date:  2017-06-23       Impact factor: 4.430

Review 8.  Involvement of inflammation and its related microRNAs in hepatocellular carcinoma.

Authors:  Ke Jin; Tong Li; Gonzalo Sánchez-Duffhues; Fangfang Zhou; Long Zhang
Journal:  Oncotarget       Date:  2017-03-28

Review 9.  Stem-like plasticity and heterogeneity of circulating tumor cells: current status and prospect challenges in liver cancer.

Authors:  Margherita Correnti; Chiara Raggi
Journal:  Oncotarget       Date:  2017-01-24

10.  Association of Preoperative NANOG-Positive Circulating Tumor Cell Levels With Recurrence of Hepatocellular Carcinoma.

Authors:  Yongrong Lei; Xishu Wang; Heng Sun; Yuna Fu; Yichen Tian; Ludi Yang; Jianhua Wang; Feng Xia
Journal:  Front Oncol       Date:  2021-05-27       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.